Association of PAI-1 4G/5G and -844G/A Gene Polymorphism and Changes in PAI-1/tPA Levels in Stroke: A Case-Control Study

Journal of Stroke and Cerebrovascular Diseases

Volumn 16, Issue 4, 2007, Pages 153-159

  Saidi, Sarra ^a   Slamia, Lamia B ^b   Mahjoub, Touhami ^a   Ammou, Sofyan B ^b   Almawi, Wassim Y ^c  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b SAHLOUL UNIVERSITY HOSPITAL   (Tunisia)

^c ARABIAN GULF UNIVERSITY   (Bahrain)

Author keywords

gene polymorphism; Plasminogen activator inhibitor 1; stroke; tissue type plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BODY MASS; BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME IMMUNOASSAY; FAMILY HISTORY; FEMALE; FIBRINOLYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; STROKE;

ADULT; AGED; ALLELES; BODY MASS INDEX; CARRIER PROTEINS; CASE-CONTROL STUDIES; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEQUENCE DELETION; SMOKING; TUNISIA;

EID: 34447291571     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2007.02.002     Document Type: Article

References (37)

1. Humphries S.E., and Morgan L. Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches. Lancet Neurol 3 (2004) 227-235
2. Kim R.J., and Becker R.C. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 146 (2003) 948-957
3. Eskandari M.K., Bontempo F.A., Hassett A.C., et al. Arterial thromboembolic events in patients with the factor V Leiden mutation. Am J Surg 176 (1998) 122-125
4. Catto A.J., Carter A.M., Stickland M., et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 77 (1997) 730-734
5. Wiklund P.G., Nilsson L., Ardnor S.N., et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 36 (2005) 1661-1665
6. Casas J.P., Hingorani A.D., Bautista L.E., et al. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol 61 (2004) 1652-1661
7. Fassbender K., Dempfle C.E., Mielke O., et al. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke 30 (1999) 2101-2104
8. Ribo M., Montaner J., Molina C.A., et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 35 (2004) 2123-2127
9. Haapaniemi E., Soinne L., Syrjala M., et al. Serial changes in fibrinolysis and coagulation activation markers in acute and convalescent phase of ischemic stroke. Acta Neurol Scand 110 (2004) 242-247
10. Nicholl S.M., Roztocil E., and Davies M.G. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol 4 (2006) 101-116
11. Kohler H.P., and Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342 (2000) 1792-1801
12. Dobrovolsky A.B., and Titaeva E.V. The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Mosc) 67 (2002) 99-108
13. Stegnar M., Uhrin P., Peternel P., et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 79 (1998) 975-979
14. Ridker P.M., Hennekens C.H., Stampfer M.J., et al. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 343 (1994) 940-943
15. Kathiresan S., Gabriel S.B., Yang Q., et al. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 112 (2005) 1728-1735
16. Verschuur M., Jellema A., Bladbjerg E.M., et al. The plasminogen activator inhibitor-1 (PAI-1) promoter haplotype is related to PAI-1 plasma concentrations in lean individuals. Atherosclerosis 181 (2005) 275-284
17. Grubic N., Stegnar M., Peternel P., et al. A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 84 (1996) 431-443
18. Henry M., Chomiki N., Scarabin P.Y., et al. Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 17 (1997) 851-858
19. Festa A., D'Agostino Jr. R., Rich S.S., et al. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Circulation 107 (2003) 2422-2427
20. Bang C.O., Park H.K., Ahn M.Y., et al. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis 11 (2001) 294-299
21. Endler G., Lalouschek W., Exner M., et al. The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol 110 (2000) 469-471
22. Hoekstra T., Geleijnse J.M., Kluft C., et al. 4G/4G genotype of the PAI-1 gene is associated with reduced risk of stroke in the elderly. Stroke 34 (2003) 2822-2828
23. Johansson L., Jansson J.H., Boman K., et al. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 31 (2000) 26-32
24. Dawson S.J., Wiman B., Hamsten A., et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268 (1991) 10739-10745
25. Mansfield M.W., Stickland M.H., and Grant P.J. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 74 (1995) 842-847
26. Eriksson P., Nilsson L., Karpe F., et al. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 18 (1998) 20-26
27. Roest M., van der Schouw Y.T., Banga J.D., et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 101 (2000) 67-70
28. Jood K., Ladenvall P., Tjarnlund-Wolf A., et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke 36 (2005) 2077-2081
29. van Goor M.L., Garcia E.G., Leebeek F., et al. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke: a case-control study. Thromb Haemost 93 (2005) 92-96
30. Hindorff L.A., Schwartz S.M., Siscovick D.S., et al. The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 9 (2002) 131-137
31. Chen C.H., Eng H.L., Chang C.J., et al. 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J Lab Clin Med 142 (2003) 100-105
32. Crainich P., Jenny N.S., Tang Z., et al. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost 1 (2003) 1799-1804
33. Luttun A., Lupu F., Storkebaum E., et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 22 (2002) 499-505
34. Rossignol P., Luttun A., Martin-Ventura J.L., et al. Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. J Thromb Haemost 4 (2006) 664-670
35. Wang X., Tsuji K., Lee S.R., et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 35 (2004) 2726-2730
36. Strickland S. Tissue plasminogen activator in nervous system function and dysfunction. Thromb Haemost 86 (2001) 138-143
37. Yang Q., Khoury M.J., Botto L., et al. Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Hum Genet 72 (2003) 636-649